Table 1.
Therapeutic targets and relative drugs in preclinical studies of fragile X syndrome.
| Targets | Drugs | Action | |
|---|---|---|---|
| Neurotransmitter receptors or transporters | mGluR5 | MPEP, CTEC, fenobam, AFQ056 | Antagonists |
| mGluR1 | JNJ16259685, LY367385 | Antagonists | |
| GABAA receptor | THIP, ganaxolone | Agonists | |
| GABAB receptor | Baclofen, arbaclofen (STX209) | Agonists | |
| 5-HT7 receptor | 8-OH-DPAT | Agonist | |
| 5-HT2B receptor | BW723C86 | Agonist | |
| 5-HT2A receptor | αMe-5HT, MDL11939 | Antagonists | |
| 5-HTT | Fluoxetine | 5-HT reuptake inhibitor | |
| Dopamine D1 receptor | SKF81297 | Agonist | |
| CB1R | Rimonabant | Antagonist | |
| CB2R | AM630 | Antagonist | |
| MGL | JZL184 | Inhibitor | |
| M1R | Dicyclomine | Antagonist | |
| M4R | Tropicamide | Antagonist | |
| NMDAR | Memantine | Antagonist | |
| Protein kinases or other enzymes | ERK | SL327, U0126, lovastatin | Inhibitors |
| JNK | SP600125 | Inhibitor | |
| PI3K | LY294002, TGX-221 | Inhibitors | |
| PTEN | BpV | Inhibitor | |
| mTOR | Temsirolimus, rapamycin, LY294002, TGX221 | Inhibitors | |
| GSK3 | Lithium, SB216763 TDZD-8, YP0.7 | Inhibitors | |
| MMP9 | Minocycline | Inhibitor | |
| PAK | FRAX486 | Inhibitor | |
| Ion channels | Kv4 channel | HpTx2 | Blocker |
| BK channel | BMS-204352 | Opener |